This latest paper highlights a Herpes simplex virus vaccine being developed in collaboration with our Swedish partners. The Advax-CpG adjuvant in this herpes simplex vaccine is the same approach as we are using in our current COVID-19 vaccine. Link to the paper: https://www.sciencedirect.com/science/article/pii/S0264410X21010987
On August 07, 2021, the first volunteer enrolled in the Phase 3 clinical study of Cinnagen’s COVID-19 vaccine candidate in Iran. The study is a randomized, double-blind, placebo-controlled trial and will evaluate the efficacy and safety of the vaccine in 16,876 adult participants. Subjects receive two doses, 21 days apart, of either COVID-19 vaccine or saline placebo...
CinnaGen Co. announced that the results of preliminary analysis of data from the ongoing Phase 2 human clinical trial of SpikoGen vaccine based on Vaxine’s COVID-19 vaccine technology were positive. This vaccine comprises a recombinant spike protein antigen formulated with the proprietary Advax-SM adjuvant. The Phase 2 study was a randomized, double-blind, placebo-controlled trial conducted on...
TV9 News spoke to Prof Nikolai Petrovsky, PhD, senior researcher, an expert on vaccine development and director of endocrinology at Flinders medical centre, Flinders University, Australia, to understand the importance of stringent lockdown measures and what can India learn from Australia’s handling of the COVID-19 pandemic. Here is the link to the full article: https://www.news9live.com/india/can-india-prevent-covid-19-third-wave-global-vaccine-expert-answers-42504.html